Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 12/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13853259 | 0.81 | CYP1A2 (0.50) | CYP1A2MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL13853264 | 0.81 | CYP1A2 (0.47) | CYP1A2MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL5262828 | 0.80 | CYP1A2 (0.49) | CYP1A2MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL13853269 | 0.80 | CYP1A2 (0.46) | CYP1A2MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL13853263 | 0.79 | CYP1A2 (0.48) | CYP1A2MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL13853266 | 0.78 | CYP1A2 (0.47) | CYP1A2MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL13686511 | 0.73 | CYP1A2 (0.50) | CYP1A2MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL13853261 | 0.72 | CYP1A2 (0.49) | CYP1A2MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL14237207 | 0.68 | KDM4E (0.59) | CYP1A2MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL14935831 | 0.67 | CYP1A2 (0.72) | CYP1A2MAPTNPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137558-A1 | Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products | PEAKDALE MOLECULAR LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137558-A1 | Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products | PEAKDALE MOLECULAR LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137558-A1 | Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products | PNPO, CYP4B1, PDXK | CYP1A2 8/4885DPP4 706/4885MAPT 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.